June 6, 2017

Acute myeloid (myelogenous, myelocytic) leukemia (AML) is a rapidly progressing blood cancer with an extremely poor overall prognosis. AML predominantly affects the elderly population and this subgroup of patients has an exceptionally high level of unmet needs. GlobalData estimates the 2014 sales for AML at approximately $342 million across the 7MM covered in this report. The market will increase by almost three-fold over the forecast period, reaching $932 million in 2024 at a CAGR of 10.5%.

Annualized AML therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments (including, young patients, elderly patients, refractory/relapsed patients and FLT3 mutated patients), forecast from 2014 to 2024.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AML therapeutics market

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidate in Phase III development is profiled.

Analysis of the current and future market competition in the global AML therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Contents of the Report

  • Introduction
  • Etiology and Pathophysiology
  • Disease Background
  • Disease Management
  • Current Treatment Options
  • Unmet Needs Assessment and Opportunity Analysis
  • R&D Strategies
  • Pipeline Assessment
  • Pipeline Valuation Analysis
  • Appendix



Key benefits of buying this profile include:

For over forty years, there have been no major advances in the treatment for AML. The AML space is filled with excitement because the first targeted FLT3 kinase inhibitor therapies are expected to change the treatment landscape. What will be the impact of these newly approved drugs on AML sales?

With the unmet needs of AML patients remaining critically high, what R&D strategies and opportunities are being used by drug makers to remain competitive?

The survival of patients with AML remains dismal, especially for those who do not respond to first-line chemotherapies. Therefore, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the AML market?

About GlobalData 

GlobalData is a leading provider of global business intelligence including market, competitor, and product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team.
About MarketsandReports.com

MarketsandReports.com is a syndicated report platform with wide variety of industry reports from reputed industry publishers. MarketsandReports.com is promoted by DART Consulting. MarketsandReports.com lists variety of reports at the best price with seasonal discounts and promotion codes.

This report is available at www.marketsandreports.com

Contact us:


Direct : + 91-80- 4224 7136, 953-807- 6063

Email: sales@marketsandreports.com

Web: www.marketsandreports.com

Share :